Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

cancer tests

- PMLiVE

NICE backs Pfizer drug in kidney cancer

Inlyta near end of two-year struggle for recommendation

- PMLiVE

Cancer Drugs Fund is not NICE replacement

Malcolm Qualie, pharmacy lead for specialised services within NHS England, speaks to PMLiVE

UK flag

UK lags behind other countries in use of branded drugs

ABPI claims use of innovative new treatments is lower than international average in seven out of 11 classes

- PMLiVE

NHS names drugs to be re-evaluated for Cancer Drugs Fund

Will assess cost-effectiveness of drugs including Kadcyla and Avastin

- PMLiVE

Charity demands action on cancer drug prices in UK

Breakthrough Breast Cancer wants commitment from all political parties

- PMLiVE

NHS England invests £120m to tackle mental health

Standards to put mental illness on equal footing with physical health issues

- PMLiVE

Cancer Drugs Fund could take on a price assessment role

NHS England consults on a series of significant changes to Fund

- PMLiVE

Janssen backs NHS diabetes challenge

Will provide £200,000 to spread innovation across UK

- PMLiVE

England’s Cancer Drugs Fund: Naughty or NICE?

The decision to extend the CDF raises questions on the future of cancer drug access on the NHS

- PMLiVE

England’s Cancer Drugs Fund receives new funding boost

Gains an extra £160m to pay for drugs not recommended by NICE

- PMLiVE

NHS England takes aim at medicines optimisation

New dashboard to support patients' medicine use has pharma support

- PMLiVE

McCarthy leaves NHS England

Policy director set for move to the University of Bradford

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links